Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Operating Leases (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Operating Leases for 7 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 14.44% year-over-year to $5.7 million, compared with a TTM value of $5.7 million through Dec 2025, down 14.44%, and an annual FY2025 reading of $5.7 million, down 14.44% over the prior year.
  • Operating Leases was $5.7 million for Q4 2025 at Karyopharm Therapeutics, down from $6.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $10.7 million in Q1 2021 and bottomed at $955000.0 in Q2 2024.
  • Average Operating Leases over 5 years is $6.2 million, with a median of $6.3 million recorded in 2025.
  • The sharpest move saw Operating Leases tumbled 78.78% in 2024, then soared 554.55% in 2025.
  • Year by year, Operating Leases stood at $9.0 million in 2021, then plummeted by 32.02% to $6.1 million in 2022, then tumbled by 54.26% to $2.8 million in 2023, then skyrocketed by 140.66% to $6.7 million in 2024, then fell by 14.44% to $5.7 million in 2025.
  • Business Quant data shows Operating Leases for KPTI at $5.7 million in Q4 2025, $6.0 million in Q3 2025, and $6.3 million in Q2 2025.